Xtant Medical Holdings, Inc. reported a total revenue of $133.9 million for the fiscal year ending December 31, 2025, marking a 14% increase from $117.3 million in 2024. This growth was primarily driven by a significant rise in license revenue, which surged to $18.7 million from $1.5 million the previous year, alongside an increase in orthobiologics sales. However, this was partially offset by a decline in hardware revenue. The company's gross profit also improved, reaching $84.3 million, or 62.9% of total revenue, compared to 58.2% in 2024, attributed to a favorable sales mix and greater operational scale.
In terms of operational changes, Xtant Medical completed the divestiture of its Coflex and CoFix product lines and its international hardware business to Companion Spine for a total of $21.4 million on December 1, 2025. This transaction included a cash payment of $1.8 million at closing and a promissory note of $8.2 million. The divestiture is expected to adversely impact the company's revenue in 2026, as it recognized $20.3 million in revenue from these product lines in 2025. Additionally, the company has been focusing on expanding its product portfolio, with recent launches including nanOss Strata™ and CollagenX™, and plans to introduce several new products in 2024.
Xtant Medical's operational metrics indicate a stable workforce, with 151 full-time employees as of December 31, 2025. The company has over 670 independent sales agents and distributors in the U.S. and maintains a presence in international markets through various distribution partners. However, the company faces challenges, including a material weakness in internal controls over financial reporting, particularly regarding inventory valuation, which could lead to misstatements in financial reporting.
Looking ahead, Xtant Medical anticipates that the loss of license revenue and product sales due to regulatory changes in reimbursement policies will negatively impact its financial performance in 2026. The company has acknowledged that the $18.7 million in license revenue recognized in 2025 is unlikely to recur, which could significantly affect future revenues and gross margins. Despite these challenges, Xtant Medical remains committed to its growth initiatives, including product innovation and market expansion, although it cannot guarantee success in these endeavors.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. develops and markets orthobiologics and spinal implant systems for treating spinal disorders. Its products include biologics, fixation, and motion preservation devices used by spine surgeons worldwide. The company leverages extensive distribution channels, strategic acquisitions, and innovative biologics to enhance patient outcomes. Focused on quality and regulatory compliance, Xtant serves the orthopedic and neurosurgical markets with a competitive edge in minimally invasive and complex spine procedures.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.